PDF(Pubmed)
Abstract：
Since the onset of the COVID-19 pandemic in March 2020, over 769 million confirmed COVID-19 cases, including close to 7 million COVID-19-related deaths, have been reported. Although mortality rates have dropped notably compared to the first months of the pandemic, spikes in reported cases and mortality rates continue to be registered. Both recent spikes in case numbers and the continued emergence of new variants suggest that vulnerable patient groups, including older adults, immunocompromised patients, and patients with severe comorbidities, are going to continue to be affected by COVID-19. In order to curb the pandemic, relieve the pressure on primary care facilities, and reduce mortality rates, global vaccination programs have been established by the WHO, with over 13.5 billion vaccine doses having been administered globally. In most immunocompetent individuals, vaccination against COVID-19 results in the production of anti-SARS-CoV-2 spike antibodies. However, certain patient subsets have inadequate or reduced immune responses, and immune responses are known to decrease with age. General recommendations on the timing of booster vaccinations may therefore be insufficient to protect vulnerable patients. This review aims to evaluate the clinical role of anti-SARS-CoV-2 antibodies, focusing on measurement indications, prognostic value, and potential as a correlate of protection to guide future booster vaccination strategies.
摘要：
自2020年3月COVID-19大流行爆发以来，确诊病例超过7.69亿例，包括近700万例与COVID-19相关的死亡，已被报道。尽管与大流行的头几个月相比，死亡率显着下降，报告的病例和死亡率继续上升。最近病例数的激增和新变异的持续出现都表明，脆弱的患者群体，包括老年人,免疫力低下的患者，有严重合并症的病人，将继续受到COVID-19的影响。为了遏制大流行，减轻初级保健设施的压力，降低死亡率，世界卫生组织已经建立了全球疫苗接种计划，全球已经接种了超过135亿剂疫苗。在大多数有免疫能力的人中，针对COVID-19的疫苗接种导致抗SARS-CoV-2尖峰抗体的产生。然而,某些患者亚群的免疫反应不足或降低，已知免疫反应会随着年龄的增长而降低。因此，关于加强疫苗接种时间的一般建议可能不足以保护脆弱的患者。本文旨在评估抗SARS-CoV-2抗体的临床作用。专注于测量指示，预后价值，以及作为保护相关因素的潜力，以指导未来的加强疫苗接种策略。
